Michelle R. Padget - Concepedia

Concepedia

Author

Michelle R. Padget

National Cancer Institute ORCID

Also Known As

Michelle Padget, Michelle R Padget, Michelle R. Padget

55

Publications

1.4K

Citations

16

H-Index

39

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research ImmunityBio (United States)National Institutes of Health National Institute on Deafness and Other Communication Disorders

MR

About

Michelle R. Padget is an author at National Cancer Institute specializing in medicine, cell biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	531
2	Cell Biology	6	6	531
3	Health Sciences	1	1	174
4	Natural Sciences	1	1	34
5	Cellular Physiology	1	1	180

Michelle R. Padget

×

17

Publications

1.4K

Citations

16

H-Index

	Year	Citations
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, Clinical Cancer Research	2020	209
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele Caroline Jochéms, James W. Hodge, Massimo Fantini, Oncotarget Lymphocyte DevelopmentImmunologyImmune RegulationImmunoeditingImmunologic Mechanism	2016	180
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer So Jin Park, Wenda Ye, Roy Xiao, Oral Oncology Neck CancerMalignant DiseasePreclinical ModelsMedicineSimilar Immunogenic Changes	2019	174
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner, Blood	2013	143
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations Kellsye P. Fabian, Michelle R. Padget, Renee N. Donahue, Journal for ImmunoTherapy of Cancer	2020	143
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition Kathleen E. Fenerty, Michelle R. Padget, Benjamin Wolfson, Journal for ImmunoTherapy of Cancer	2018	68
Overcoming hypoxia-induced functional suppression of NK cells Kristen Solocinski, Michelle R. Padget, Kellsye P. Fabian, Journal for ImmunoTherapy of Cancer	2020	65
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK Amber Giles, Shuyu Hao, Michelle R. Padget, JCI Insight ImmunologyCell DeathImmunotherapeuticsImmunotherapyGlioma	2019	60
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells Yvette Robbins, Sarah Greene, Jay Friedman, eLife Cell TherapyTumor ControlImmunologyImmunoeditingNk Cells	2020	57
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve Kellsye P. Fabian, Michelle R. Padget, Rika Fujii, Journal for ImmunoTherapy of Cancer	2021	50

Page 1